Reuters logo
5 months ago
BRIEF-Bavarian Nordic: collaboration to evaluate CV301 and Tecentriq in bladder cancer
March 10, 2017 / 9:09 AM / 5 months ago

BRIEF-Bavarian Nordic: collaboration to evaluate CV301 and Tecentriq in bladder cancer

March 10 (Reuters) - Bavarian Nordic A/S:

* Announces collaboration to evaluate CV301 and tecentriq in bladder cancer

* Agreement with F. Hoffmann-La Roche Ltd (Roche) whereby Roche has agreed to supply their PD-L1 blocking antibody Tecentriq (atezolizumab) for a clinical study combining Bavarian Nordic's cancer vaccine, CV301, and Tecentriq in patients with urothelial carcinoma, or bladder cancer

* Roche has committed to supplying Tecentriq to Bavarian Nordic during the phase 2 trial

* Bavarian Nordic will be responsible for conducting clinical trial, and both companies will share data from trial

* Bavarian Nordic continues to retain all commercial rights to CV301

Source text for Eikon:

Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below